A Criminal Investigation Has Been Launched Into A Maker Of An Alzheimer’s Drug!

A criminal investigation has been launched by the U.S. Department of Justice into a manufacturer of an Alzheimer’s drug over allegations that the company fabricated research findings for the drug, according to an exclusive report from Reuters.

Authorities in the U.S. are reportedly conducting an investigation into Cassava, focused on whether it manipulated research results, according to Reuters sources.

They are looking into whether companies or individuals misled or defrauded investors, government agencies, or consumers, although no specific details were provided, and the investigation could close without any charges, Reuters said.

According to Daily Wire, “the investigation comes after a bombshell report was published last week in Science Magazine about how key images from one of the most cited research papers on Alzheimer’s disease this century might have been intentionally fabricated, throwing off years and hundreds of millions of dollars worth of taxpayer-funded research into the seventh leading cause of death in the United States.”

A lawyer representing Cassava, Kate Watson Moss, did not confirm or deny the criminal probe, she told Reuters in an email that “Cassava Sciences vehemently denies any and all allegations of wrongdoing.”

Adding that the company “has never been charged with a crime, and for good reason – Cassava Sciences has never engaged in criminal conduct.”

More details of this report from The Daily Wire:

Matthew Schrag, a neuroscientist, and physician at Vanderbilt University, stumbled upon the controversial study while investigating an experimental drug for Alzheimer’s called Simufilam, which is manufactured by Cassava Sciences.

Schrag was contacted by an attorney that was investigating the drug on behalf of two prominent neuroscientists who said that some of the research behind the drug was “fraudulent.”

The report in Science Magazine then pivots to how Schrag’s investigation into the drug eventually led him to investigating a 2006 study published in Nature by neuroscientist Sylvain Lesné of the University of Minnesota (UMN) that “underpins a key element of the dominant yet controversial amyloid hypothesis of Alzheimer’s, which holds that [protein amyloid beta] Aβ clumps, known as plaques, in brain tissue are a primary cause of the devastating illness,” Science reported.

Science investigated the study and says it corroborated Schrag’s suspicions about Lesné’s research with the help of leading Alzheimer’s researchers and image analysts. The independent experts alleged that some images they reviewed were “shockingly blatant” examples of image tampering.

The authors “appeared to have composed figures by piecing together parts of photos from different experiments,” Elisabeth Bik, a molecular biologist and well-known forensic image consultant, told the publication. “The obtained experimental results might not have been the desired results, and that data might have been changed to … better fit a hypothesis.”

The report noted that the implication of the suspected fraudulent work means that hundreds of millions of dollars in taxpayer funds from the National Institutes of Health (NIH) might have been wasted, and that the entire scientific field could have been searching in the wrong direction for the last 16 years for a cure for Alzheimer’s since thousands of studies were based on the study in question.

Watson Moss stated Cassava has received confidential requests for information from government agencies but did not identify the agencies.

Cassava is already facing scrutiny from the SEC and investors after allegations of data manipulation and misrepresentation involving research for its Alzheimer’s drug, simufilam.

Sources: TheDailyWire, Reuters, Science.org